The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a pointy drop in revenues this 12 months owing to a push by Donald Trump to decrease US weight-loss drug costs, rising competitors and the lack of key patent protections.
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
